January 10, 2023 12:30 PM ESTUpdated 04:54 PM
R&D

Mar­ket­ingRx roundup: Blue­bird bio pro­motes sick­le cell aware­ness; Pfiz­er, BioN­Tech en­cour­age boost­ers in South

Beth Snyder Bulik

Senior Editor

While blue­bird bio is ex­pect­ed to file an ap­pli­ca­tion with the FDA for its sick­le cell dis­ease (SCD) drug can­di­date in the first quar­ter, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times